Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 28, 2014; 20(40): 14537-14558
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14537
Table 2 Phase II trials of epidermal growth factor receptor tyrosine kinase inhibitors for advanced gastric cancer and gastro-esophageal junction cancers
Author/trialPhaseSettingRegimenPatients (n)RROS (mo)TTP (mo)
NCT00237900[86], 2010IINeoadjuvantCF + G + RT80-42% (3-yr)-
SWOG 0127[89], 2006II1st lineErlotinib 150 mg/d44 (GEJ)9% (GEJ)6.7 (GEJ)-
26 (stomach)0% (stomach)3.5 (stomach)-